Endocrine therapy, like selective oestrogen receptor modulator and aromatase inhibitors in breast cancer, targeted agents like vascular endothelial growth factor (VEGF) inhibitors (Sunitinib and Bevacizumab) and lenalidomide has been known to cause cognitive impairment [32]. This evidence concerns the gene CYP19A1 and Cognitive impairment.